Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

Hepatology

Volumn 63, Issue 4, 2016, Pages 1112-1119

  Saab, Sammy ^a   Park, Sarah H ^a   Mizokami, Masashi ^b   Omata, Masao ^c   Mangia, Alessandra ^d   Eggleton, Ed ^e   Zhu, Yanni ^e   Knox, Steven J ^e   Pang, Phil ^e   Subramanian, Mani ^e   Kowdley, Kris ^f   Afdhal, Nezam H ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e GILEAD SCIENCES   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS C; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; AGE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; EVALUATION STUDY; FOLLOW UP; GENETICS; GENOTYPE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; SEX FACTORS; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84959235497     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28425     Document Type: Article

References (38)

1. Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014;39:518-531.
2. Perz JF, Farrington LA, Pecoraro C, Hutin YJF, Armstrong GL. Estimated global prevalence of hepatitis C virus infection. Presented at: 42nd Annual Meeting of the Infectious Diseases Society of America; Sept 30-Oct 3, 2004; Boston, MA.
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-538.
4. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillian GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293-300.
5. Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol 2014;60:691-698.
6. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-338.
7. World Health Organization. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44:20-29.
8. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012;55(Suppl. 1):S10-S15.
9. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012;157:817-822.
10. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of the hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-521.
11. Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, et al. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl 2012;18:1471-1478.
12. Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group (Hepatitis C European Network for Co-operative Research). Eur J Gastroenterol Hepatol 2000;12:667-678.
13. Mangia A, Clemente R, Musto P, Cascavilla I, La Floresta P, Sanpaolo G, et al. Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. Leukemia 1996;10:1209-1213.
14. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 2006;45:607-616.
15. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010;53:39-43.
16. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-587.
17. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010;8:192-199.
18. Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
19. Nudo CG, Wong P, Hilzenrat N, Deschênes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 2006;20:589-592.
20. Saab S, Oh MK, Ibrahim AB, Durazo F, Han S, Yersiz H, et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007;13:1032-1038.
21. Takaki S, Tsubota A, Hosaka T, Akuta N, Someya T, Kobayashi M, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004;39:668-673.
22. Nomura H, Tanimoto H, Kajiwara E, Shimono J, Maruyama T, Yamashita N, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004;19:1312-1317.
23. Roeder C, Jordan S, Schulze Zur Wiesch J, Pfeiffer-Vornkahl H, Hueppe D, Mauss S, et al. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol 2014;20:10984-10993.
24. Honda T, Katano Y, Shimizu J, Ishizu Y, Doizaki M, Hayashi K, et al. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 2010;30:527-537.
25. Antonucci G, Angeletti C, Vairo F, Longo A, Girardi E. Age and prediction of sustained virological response to hepatitis C virus (HCV) infection treatment based on 28-day decrease in HCV RNA levels. J Infect Dis 2009;200:1484-1485.
26. Thabut D, Le Calvez S, Thibault V, Massard J, Munteanu M, Di Martino V, et al. Hepatitis C in 6, 865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006;101:1260-1267.
27. Saab S, Rheem J, Sundaram V. Hepatitis C infection in the elderly. Dig Dis Sci 2015;60:3170-3180.
28. US Food and Drug Administration, Center for Drug Evaluation and Research. Harvoni approval letter, March 2015. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed August 5, 2015.
29. Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015;62:79-86.
30. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and sofosbuvir for HCV in patients co-infected with HIV-1. N Engl J Med 2015;373:705-713.
31. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-659.
32. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
33. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
34. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
35. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15:645-653.
36. Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15:397-404.
37. Younossi ZM, Stepanova M, Afdhal N, Kowdley KV, Zeuzem S, Henry L, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015;63:337-345.
38. Younossi ZM, Stepanova M, Nader F, Lam BP, Afendy M, Cable R, Hunt SL . Improvement of patient-reported outcomes in older patients with chronic hepatitis C (CH-C) treated with interferon- and ribavirin-free sofosbuvir (SOF)-containing regimens. DigGastroenterology 2015;148:S-979.